TOFRANIL
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Oct 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 5h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TOFRANIL (imipramine) is a tricyclic antidepressant approved in 1959 that works by blocking the reuptake of norepinephrine at nerve endings, potentiating adrenergic synapses. It is indicated primarily for depression and childhood enuresis, with the enuresis mechanism distinct from its antidepressant activity. Administered via injection, it represents a legacy small-molecule therapeutic with over 60 years of clinical use.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30%), indicating a consolidating market and likely reduced headcount growth on brand team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
To Demonstrate the Relative Bioavailability of Sandoz Inc. and Tyco Healthcare (Tofranil) 50 mg Imipramine Hydrochloride Tablets In Healthy Adults Volunteers Under Fasting Conditions
Started Jul 2005
48 enrolled
Depression
Career Relevance
Working on TOFRANIL offers experience in legacy product management, market defense, and cost-effective commercial operations in a declining therapeutic category. This role is best suited for professionals skilled in maintaining market position and managing transitions rather than driving growth.
Brand Manager
Worked on TOFRANIL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.